Category: DISEASE ADVANCES - Page 3 - Start Medical Product Development

Senescent astrocytes discovered in Alzheimer’s brains point to new treatment targets

February 16, 2026

Researchers from the NeuroAD group (Neuropathology of Alzheimer’s Disease) within the Department of Cell Biology, Genetics and Physiology at the University of Málaga, also affiliated with IBIMA–BIONAND Platform and CIBERNED, have made a pioneering breakthrough in the fight against this disease by identifying astrocytes as a promising cellular target for the development of future therapies.

AI model flags insulin resistance as a risk factor for 12 cancers

February 16, 2026

For the first time, researchers, including those from the University of Tokyo, applied a machine learning-based prediction model of insulin resistance to half a million participants from the UK Biobank and demonstrated that insulin resistance is a risk factor for 12 types of cancer.

A 15-minute VR eye test could flag vision changes tied to brain health

February 14, 2026

In the recreation room at Eskaton Village in Carmichael, Bonnie Dale, one of the residents, is trying on a virtual reality (VR) headset.

A patch that sticks inside your mouth could spot inflammation early

February 14, 2026

The specialized sensing layer of the patch targets the tumor necrosis factor-alpha (TNF-⍺) protein, a key biomarker for inflammation.

Novocure wins FDA approval to treat pancreatic cancer with electric fields

February 13, 2026

Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.

InVera Medical Achieves European CE Mark Approval for New Vein Infusion Device

February 13, 2026

GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ — InVera Medical, an Irish medical technology company, has received European regulatory approval for a new minimally invasive device designed to help physicians deliver treatment more effectively to diseased leg veins, including varicose veins.

World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors

February 13, 2026

TAICHUNG, Feb. 13, 2026 /PRNewswire/ — Cancer has long ranked among the leading causes of death in Taiwan, and solid tumors account for more than 90% of cancer cases worldwide—making them the most challenging frontier for CAR-T cell therapy. China Medical University Hospital (CMUH) announced today that, in collaboration with Ever Supreme Bio Technology, it has successfully developed the world’s first EXO 001 targeted exosome platform, a breakthrough technology that enables direct in vivo programming of T cells to generate multi-target nanobody-based CAR-T cells.